Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pediatrix Medical (MD)

Pediatrix appoints Kurt Newman, former Children's National CEO, as independent director

Neutral Impact 2 of 5 leadership Written later

Pediatrix Medical Group's board appointed Dr. Kurt Newman as an independent director, effective July 1, 2025. He is a former President and CEO of Children's National Hospital, and he has not yet been named to any board committee. The filing reports no financial results, so the change is a board composition update for shareholders.

Key points

  • Appointed as a director effective July 1, 2025; not yet named to any board committee.
  • Served as President and CEO of Children's National Hospital for 12 years, after more than 25 years there as a pediatric surgeon.
  • Receives standard non-employee director compensation and will enter the company's standard indemnification agreement.
  • Filing states no related-person transactions above $120,000 since the start of the last fiscal year, other than as described.

The filing

CompanyPediatrix Medical (MD)
Form8-K, current report
Filed with the SECJul 1, 2025, 4:30 PM ET
Accession number0000950170-25-092261

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.